Which potential side effect is associated with Sumatriptan?

Sumatriptan is a medication primarily used for the acute treatment of migraine headaches. One of the notable side effects associated with the use of triptans, including sumatriptan, is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This condition involves a sudden loss of vision due to reduced blood flow to the optic nerve, and while it's a rare event, there is enough evidence to suggest that the use of triptans, particularly in patients who may already have predisposing factors, can increase the risk of developing NAION.

Triptans work as agonists at serotonin receptors, which can induce vasoconstriction in cranial blood vessels and influence blood flow dynamics, potentially leading to vascular events affecting the optic nerve. This side effect highlights the importance of careful patient selection and monitoring when prescribing sumatriptan, especially for individuals who may have risk factors for ocular ischemic conditions.

In contrast, the other options do not have a significant or established connection with sumatriptan. Nigrostriatal dysfunction is generally associated with Parkinson's disease and dopaminergic medications, while retinal detachment is linked to other risk factors and conditions rather than sumatriptan use. Hepatotoxicity